<DOC>
	<DOCNO>NCT02572219</DOCNO>
	<brief_summary>Aim randomize , double-blind clinical study evaluate efficacy nutraceutical preparation early marker cognitive impairment , patient affect arterial hypertension .</brief_summary>
	<brief_title>Effects Nutraceutical Preparation Cognitive Impairment Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Written inform consent ; Males females 40 65 year age ; Hypertensive patient classify accord SBP ( Systolic Blood Pressure ) DBP ( Diastolic Blood Pressure ) value . Included patient stage 1 hypertension ( SBP 140159 mmHg ; DBP 9099 mmHg ) stage 2 hypertension ( SBP 160179 mmHg ; DBP 100109 mmHg ) . Previous acute myocardial infarction ( AMI ) ; Previous stroke and/or transient ischemic attack ( TIA ) ; Diabetes mellitus ; History atrial fibrillation severe arrhythmia ; Severe cardiovascular disease ; Renal pathology ( creatinine &gt; 1.4 mg/dL ) ; Preexisting psychiatric pathology ; Neurodegenerative disease , multiple sclerosis , lateral amyotrophic sclerosis , Parkinson , Alzheimer , neuromuscular pathology , epilepsy ; Diagnosis dementia ; Depression ; Longterm regular use anxiolytic drug , antidepressant drug , antipsychotic drug , hypnoinducing drug , cognitive stimulators .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>